A Phase I, Open-label, Multi-center, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of HMPL-453 in Patients With Advanced Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Hmpl 453 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Hutchison MediPharma
- 14 Feb 2017 According to a Hutchison China MediTech Limited media release, first drug dose was administered.
- 08 Feb 2017 Status changed from not yet recruiting to recruiting.
- 22 Nov 2016 New trial record